Insulin Lispro (Humalog) Pharmacology Podcast

Insulin lispro, marketed as Humalog, serves as a rapid-acting insulin essential for managing postprandial blood glucose spikes. It functions by stimulating glycogen synthesis and facilitating glucose uptake into cells, a process that simultaneously drives potassium into cells and can lead to hypokalemia, particularly in intravenous hospital settings. Clinical management requires careful monitoring to prevent hypoglycemia and weight gain, especially when using carb-to-insulin ratios for mealtime coverage. Sliding scale regimens are generally discouraged in favor of proactive, scheduled dosing to avoid reactive blood sugar management. Practitioners must account for drug interactions, such as the hyperglycemic effects of corticosteroid bursts, which necessitate temporary insulin adjustments. Vigilant assessment of patient health, diet, and concurrent medications remains critical to maintaining safe glycemic control and avoiding life-threatening fluctuations in blood sugar and electrolyte levels.